UNIVERSITAS
GADJAH MADA
ASSOCIATION BETWEEN INTERLEUKIN-6 AND MORTALITY IN SEVERE AND CRITICAL COVID-19 PATIENTS
Raden Roro Amalia Rosita, dr. Doni Priambodo, Sp.PD-KPTI , Dr.dr. Ayu Paramaiswari, Sp.PDâ€“KR, FINASIM
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Table of Contents

RATIFICATION PAGE *2*
PLAGIARISM FREE STATEMENT *3*
ACKNOWLEDGEMENT *4*
Table of Contents *6*
CHAPTER I INTRODUCTION *8*
A. Background **8**
B. Research question **9**
C. Objective **9**
D. Benefit of the study **10**
E. Originality of the research **11**
CHAPTER II LITERATURE REVIEW *12*
A. COVID-19 ..... **12**
B. Interleukin-6 (IL-6) **17**
1) Infection from a Different Source 18
2) Kidney Injury (Acute) 19
3) Septic Fever 19
4) Disseminated Intravascular Coagulation 19
5) Clots in the Blood 19
6) Children with Multisystem Inflammatory Syndrome 20
7) Chronic Fatigue Syndrome 20
8) Rhabdomyolysis 21
C. Complication of COVID-19 ..... **23**
D. Mortality **24**
E. Theoretical Framework **28**
F. Conceptual Framework **28**
G. Hypothesis **29**
CHAPTER III RESEARCH METHODOLOGY *30*
A. Research Design **30**
B. Research Population **30**

UNIVERSITAS
GADJAH MADA
ASSOCIATION BETWEEN INTERLEUKIN-6 AND MORTALITY IN SEVERE AND CRITICAL COVID-19 PATIENTS
Raden Roro Amalia Rosita, dr. Doni Priambodo, Sp.PD-KPTI , Dr.dr. Ayu Paramaiswari, Sp.PDâ€“KR, FINASIM
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

C. Inclusion Criteria..... 30
D. Exclusion Criteria..... 31
E. Sample Size..... 31
F. Study Variables..... 31
G. Operational Definition..... 32
H. Data Analysis..... 33
I. Ethical Consideration..... 34
CHAPTER IV RESULT AND DISSCUSSION..... 35
A. Patient's Characteristic..... 35
B. ROC Curve..... 38
C. Proportion Difference..... 39
D. Chi Squared Test..... 39
E. Discussion..... 40
CHAPTER V CONCLUSION AND SUGGESTION..... 43
A. Conslusion..... 43
B. Suggestion..... 43
References..... 45